Leadership Team

Jim Broderick, M.D.
CEO and Founder

Li Peng, Ph.D.
Chief Scientific Officer

Bob Sikorski, M.D., Ph.D.
Consulting Chief Medical Officer

Karl Normington, Ph.D.
VP, Intellectual Property & Strategy

John Hennessy
VP, Operations & Finance

Senior R&D Advisors

  • Rakesh Dixit, Ph.D
    Senior Consultant, Translational Science & Safety
  • Rob Kramer, Ph.D.
    Senior Consultant, Research & Development

Board of Directors

  • Jim Broderick, M.D.
    Palleon Pharmaceuticals
  • Rajeev Dadoo, Ph.D.
    SR One
  • Steve Hoffman, M.D., Ph.D.
    Independent Director
  • Bill Burkoth
    Pfizer Ventures
  • Lori Hu
    Vertex Ventures HC
  • Jayson Punwani, Ph.D.
    Takeda Ventures, Inc.


Jim Broderick, M.D.
CEO and Founder

Carolyn Bertozzi, Ph.D.

Paul Crocker, Ph.D.

Scientific Advisors

  • Carolyn Bertozzi, Ph.D.
    Stanford University
  • Paul Crocker, Ph.D.
    University of Dundee
  • Stephan von Gunten, M.D. Ph.D.
    University of Bern
  • Heinz Läubli, M.D., Ph.D.
    University of Basel
  • James Paulson, Ph.D.
    Scripps Research Institute
  • Jeffrey Ravetch, Ph.D.
    Rockefeller University
  • Joy Burchell, Ph.D.
    Kings College London
  • Paul Moss, M.D., Ph.D.
    University of Birmingham
  • Peter Murray, Ph.D.
    Max Planck Institute


Palleon is advancing its platform and programs with a $47.6 million Series A investment round that includes participation by: